| abstract |
anti-nkg2a antibodies and uses thereof. the present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, which specifically bind to human natural killer cell inhibitor receptor group 2a (nkg2a) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-nkg2a antibodies of the invention are also provided. nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treating, for example, cancer using the antibodies are further provided. combination therapy, wherein an anti-nkg2a antibody in the present invention is co-administered with at least one additional agent, such as another antibody (e.g., anti-pd-1, anti-pd-11 and/or anti-ctla- 4), is also provided. |